| Description |
Recombinant Human HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein is expressed from HEK293 with His tag and Avi Tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M) and YTDNWLAVY peptide.. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q5SUL5(HLA-A*01:01)&P61769(B2M)&YTDNWLAVY |
| Target Symbol |
HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer |
| Species |
Human |
| Expression System |
HEK293 |
| Tag |
C-His-Avi |
| Expression Range |
Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M)and YTDNWLAVY peptide. |
| Mol. Weight |
The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC. |
